1. ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome.
- Author
-
Cheong M, Gartlan KH, Lee JS, Tey SK, Zhang P, Kuns RD, Andoniou CE, Martins JP, Chang K, Sutton VR, Kelly G, Varelias A, Vuckovic S, Markey KA, Boyle GM, Smyth MJ, Engwerda CR, MacDonald KPA, Trapani JA, Degli-Esposti MA, Koyama M, and Hill GR
- Subjects
- Animals, Apoptosis, Caspase 1 metabolism, Disease Models, Animal, Female, Graft vs Host Disease etiology, Graft vs Host Disease metabolism, Inflammasomes metabolism, Leukemia immunology, Leukemia pathology, Mice, Mice, Inbred BALB C, Bone Marrow Transplantation adverse effects, CARD Signaling Adaptor Proteins metabolism, CD8-Positive T-Lymphocytes immunology, Graft vs Host Disease immunology, Inflammasomes immunology, Leukemia therapy, T-Lymphocytes, Cytotoxic immunology
- Abstract
The adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) is known to facilitate caspase-1 activation, which is essential for innate host immunity via the formation of the inflammasome complex, a multiprotein structure responsible for processing IL1β and IL18 into their active moieties. Here, we demonstrated that ASC-deficient CD8
+ T cells failed to induce severe graft-versus-host disease (GVHD) and had impaired capacity for graft rejection and graft-versus-leukemia (GVL) activity. These effects were inflammasome independent because GVHD lethality was not altered in recipients of caspase-1/11-deficient T cells. We also demonstrated that ASC deficiency resulted in a decrease in cytolytic function, with a reduction in granzyme B secretion and CD107a expression by CD8+ T cells. Altogether, our findings highlight that ASC represents an attractive therapeutic target for improving outcomes of clinical transplantation., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF